NSD2 and Miyoshi myopathy: The study concluded that the histone methyltransferase NSD2 stabilized SRC-3 protein levels, and pharmacological interference with SRC-3 abrogated this interaction, resynthesizing MM cells to BTZ in both in vitro and in vivo models [70].